Global Custom Antibody Services Market By Type (Monoclonal, and Polyclonal), By End User (Pharmaceutical & Biotechnology Companies, Research Institutions And Contract Research Organizations), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Custom Antibody Services Market By Type (Monoclonal, and Polyclonal), By End User (Pharmaceutical & Biotechnology Companies, Research Institutions And Contract Research Organizations), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)
Trusted Business Insights has published a comprehensive market research report on, Custom Antibody Services Market by Product Type (Monoclonal Antibodies and Polyclonal Antibody), by End-User (Pharmaceutical & Biotechnology Companies, Research Institutions and Contract Research Organizations), and by Region -Global Forecast to 2030, which offers a holistic view of the Global Custom Antibody Services Market through systematic segmentation that covers every aspect of the target market.

The Global Custom Antibody Services Market was valued at US$ 386.2 Mn in 2020 and is expected to reach US$ 904.1 Mn by 2030 at a CAGR of 8.9%.

Custom antibody services include competitively priced packages and purification options for antibody production. Complete service for antibody production consists of several steps from antigen preparation to final production and purification. While preparing antibodies critical factors to consider are the starting material including DNA vector or ascites fluid; the appropriate host, such as rabbit or mouse; and turn-around time. Companies also immunise with recombinant proteins or protein fragments provided by customers to generate antibodies in rabbits, chickens, goats, guinea pigs, mice, or rats. The quality of catalogue antibodies is a major area of concern for end-users, due to which end-users primarily prefer custom-made antibodies. Custom antibody holds diverse applications since these are widely used in oncology, infectious diseases, neurobiology, stem cells, immunology, cardiovascular disease, and other research areas, resulting in the stable growth of the market worldwide.

Robust growth in the pharmaceuticals industry, particularly in developing economies is creating several opportunities in this market. Also, increased research activities in life sciences industries, coupled with growing proteomics and genomics research is further expected to propel market growth.


Global Custom Antibody Services Market Revenue (US$ Mn), 2021 to 2030


Furthermore, growing awareness and quality concerns regarding antibodies are driving end-users towards custom-made antibodies, further contributing to custom antibody services market growth.
However, the high cost of initial investment for the development of custom antibodies along with stringent regulatory compliance is a major factor hampering custom antibody market growth over the forecast period. Nonetheless increasing demand for custom medicine and rise in demand for antibody-based therapeutics is creating lucrative opportunities in the market attracting major global players boosting the growth of custom antibody services market globally.

Global Custom Antibody Services market is segmented on the basis of product type, end-user and region. On the basis of product type, the market is segmented into monoclonal antibody and polyclonal antibody. Monoclonal antibody segment accounts for the majority share in the global custom antibody services market. Also, it is expected to register the highest growth rate over the forecast period. Based on end user, the market is segmented into pharmaceutical & biotechnology companies, research institutions and contract research organizations. Pharmaceutical & biotechnology companies account for a majority share in the global custom antibody services market while research institutions are expected to register the highest growth rate.


Global Custom Antibody Services MarketAttractiveness Analysis by Product Type, 2012“2018


On the basis of region, the market is segmented into North America, Europe, APAC, South America and MEA. North America accounts for the majority share in the global custom antibody services market followed by Europe owing to robust growth in pharmaceuticals and biotechnology industries in this region. Asia Pacific region is expected to register the highest growth rate over the forecast period.

The research report on the global custom antibody services market includes profiles of some of the major companies such as Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Abcam plc, Rockland Immunochemicals, Inc., Creative Biolabs Inc., RayBiotech, Inc. and Covance Inc.



Below are the active patents related to Custom Antibody Services Market.


Patent Number: US20120329994A1

Production of a Monoclonal Antibody Therapeutic Against West Nile Virus in Plants

Abstract

The present invention describes the plant-based production of a therapeutic antibody against West Nile Virus.

Application File Date: 2011-01-10

Application Granted Date: 2014-03-04

Current Assignee: Arizona Board of Regents of ASU

Key Market Segments

By Type

  
Monoclonal
  
Polyclonal

BY Application

  
Pharmaceutical & Biotechnology Companies
  
Research Institutions and Contract Research Organizations


Key Market Players included in the report:


  
Abcam
  
Abgent.
  
Biocompare
  
Bio-Rad
  
Capra Science
  
Covance
  
GenScript
  
GL Biochem
  
Innovagen
  
LIFE SCIENCE GROUP
  
MBS
  
ProSci
  
Randox
  
ROCKLAND
  
ThermoFisher


Below are the key development related to Custom Antibody Services Market in 2020 and 2021.


June 2021: Health-Care Firm BioLegend Mulls $4 billion-Plus Sale. BioLegend Inc. is exploring a sale that could value the U.S. health-care company at more than $4 billion, according to people familiar with the matter. Source

June 2021: Pre-competitive multi-partner industry collaboration aims to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain.the Wyss Institute for Biologically Inspired Engineering at Harvard University announces that it is collaborating with multiple industry partners to discover more effective approaches to deliver drugs across the blood-brain barrier (BBB) for the treatment of brain diseases. The main goals of the initiative will be to identify transport target proteins in the BBB and to develop antibody compounds that bind to these targets to facilitate the delivery of future therapeutics to the brain. The pharmaceutical companies Bristol-Myers Squibb Company, U.S.A.; Eisai Inc., Japan; and H. Lundbeck A/S, Denmark; are equally supporting this research effort and will share in the programs findings to inform their own drug development activities. Through the Massachusetts Life Science Centers Novel Therapeutics Delivery program, the collaboration was recently awarded a $750,000 grant as additional support. Source

May 2020: Abcellera, announced that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) for the discovery of antibodies for up to nine Lilly-selected therapeutic targets. Lilly will have the rights to develop and commercialize therapeutic products resulting from the collaboration.Applying best-in-class technology and custom innovation to each project, AbCellera partners with leading pharma and biotech to enable programs for any target class. With more than 55 successfully completed programs, AbCellera is transforming the field of biologics by reducing the time it takes to identify lead candidates and advance new products towards the clinic  Source